Anti-C1q antibodies
The antibodies target C1q’s complement-independent functions, with or without inhibiting the classical complement cascade.
Source: LinkedIn company description · Retrieved October 13, 2026
Montis Biosciences is a preclinical-stage biopharmaceutical company advancing therapeutics for inflammation-driven autoimmune disorders and neurodegenerative diseases.
Montis uses a patient-centric discovery platform to advance antibodies for patients with autoimmune and neurodegenerative diseases. Montis’ second program, MB02, focuses on inhibiting CD93 in lung squamous cell carcinoma.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The antibodies target C1q’s complement-independent functions, with or without inhibiting the classical complement cascade.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.